Skip to main content
SearchLoginLogin or Signup

Reviews of "Effectiveness of COVID-19 Vaccines Against Variants of Concern in Ontario, Canada"

Reviewers: R Russell (Memorial University of Newfoundland) | ๐Ÿ“˜๐Ÿ“˜๐Ÿ“˜๐Ÿ“˜๐Ÿ“˜

Published onApr 26, 2022
Reviews of "Effectiveness of COVID-19 Vaccines Against Variants of Concern in Ontario, Canada"
key-enterThis Pub is a Review of
Effectiveness of mRNA and ChAdOx1 COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe outcomes with variants of concern in Ontario
Description

ABSTRACTSARS-CoV-2 variants of concern (VOC) are more transmissible and have the potential for increased disease severity and decreased vaccine effectiveness. We estimated the effectiveness of BNT162b2 (Pfizer-BioNTech Comirnaty), mRNA-1273 (Moderna Spikevax), and ChAdOx1 (AstraZeneca Vaxzevria) vaccines against symptomatic SARS-CoV-2 infection and COVID-19 hospitalization or death caused by the Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), and Delta (B.1.617.2) VOCs in Ontario, Canada using a test-negative design study. Effectiveness against symptomatic infection โ‰ฅ7 days after two doses was 89โ€“92% against Alpha, 87% against Beta, 88% against Gamma, 82โ€“89% against Beta/Gamma, and 87โ€“95% against Delta across vaccine products. The corresponding estimates โ‰ฅ14 days after one dose were lower. Effectiveness estimates against hospitalization or death were similar to, or higher than, against symptomatic infection. Effectiveness against symptomatic infection is generally lower for older adults (โ‰ฅ60 years) compared to younger adults (<60 years) for most of the VOC-vaccine combinations.

To read the original manuscript, click the link above.

Reviewer 1 (Rod Rโ€ฆ) | ๐Ÿ“˜๐Ÿ“˜๐Ÿ“˜๐Ÿ“˜๐Ÿ“˜

RR:C19 Strength of Evidence Scale Key

๐Ÿ“• โ—ป๏ธโ—ป๏ธโ—ป๏ธโ—ป๏ธ = Misleading

๐Ÿ“™๐Ÿ“™ โ—ป๏ธโ—ป๏ธโ—ป๏ธ = Not Informative

๐Ÿ“’๐Ÿ“’๐Ÿ“’ โ—ป๏ธโ—ป๏ธ = Potentially Informative

๐Ÿ“—๐Ÿ“—๐Ÿ“—๐Ÿ“—โ—ป๏ธ = Reliable

๐Ÿ“˜๐Ÿ“˜๐Ÿ“˜๐Ÿ“˜๐Ÿ“˜ = Strong

To read the reviews, click the links below.ย 


Comments
0
comment

No comments here

Why not start the discussion?